{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:14:39Z","timestamp":1771028079520,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972889"],"award-info":[{"award-number":["81972889"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Digit Imaging. Inform. med."],"DOI":"10.1007\/s10278-024-01003-2","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T14:06:46Z","timestamp":1708697206000},"page":"1282-1296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and Preliminary Validation of a Novel Convolutional Neural Network Model for Predicting Treatment Response in Patients with Unresectable Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy"],"prefix":"10.1007","volume":"37","author":[{"given":"Bing","family":"Quan","sequence":"first","affiliation":[]},{"given":"Jinghuan","family":"Li","sequence":"additional","affiliation":[]},{"given":"Hailin","family":"Mi","sequence":"additional","affiliation":[]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[]},{"given":"Wenfeng","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Fan","family":"Yao","sequence":"additional","affiliation":[]},{"given":"Rongxin","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Yan","family":"Shan","sequence":"additional","affiliation":[]},{"given":"Pengju","family":"Xu","sequence":"additional","affiliation":[]},{"given":"Zhenggang","family":"Ren","sequence":"additional","affiliation":[]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70:151-171","journal-title":"J Hepatol"},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/hep.27745","volume":"62","author":"S Roayaie","year":"2015","unstructured":"Roayaie S, Jibara G, Tabrizian P et al (2015) The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 62:440-451","journal-title":"Hepatology"},{"key":"1003_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390","journal-title":"N Engl J Med"},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163-1173","journal-title":"Lancet"},{"key":"1003_CR5","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.21.00163","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Bi F, Gu S et al (2021) Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial. J Clin Oncol 39:3002-3011","journal-title":"J Clin Oncol"},{"key":"1003_CR6","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382:1894-1905","journal-title":"N Engl J Med"},{"key":"1003_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4003","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T et al (2023) Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4003","journal-title":"JAMA Oncol"},{"key":"1003_CR8","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739","journal-title":"Lancet"},{"key":"1003_CR9","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"CM Lo","year":"2002","unstructured":"Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171","journal-title":"Hepatology"},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1148\/radiol.12111550","volume":"263","author":"M Pinter","year":"2012","unstructured":"Pinter M, Hucke F, Graziadei I et al (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263:590-599","journal-title":"Radiology"},{"key":"1003_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/sj.bjc.6602742","volume":"93","author":"H Ota","year":"2005","unstructured":"Ota H, Nagano H, Sakon M et al (2005) Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93:557-564","journal-title":"Br J Cancer"},{"key":"1003_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1872-034X.2008.00338.x","volume":"38","author":"M Yoshikawa","year":"2008","unstructured":"Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H (2008) Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38:474-483","journal-title":"Hepatol Res"},{"key":"1003_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/j.1872-034X.2011.00905.x","volume":"42","author":"M Monden","year":"2012","unstructured":"Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E (2012) 5-fluorouracil arterial infusion\u2003+\u2003interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Hepatol Res 42:150-165","journal-title":"Hepatol Res"},{"key":"1003_CR14","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/bjc.2013.542","volume":"109","author":"K Nouso","year":"2013","unstructured":"Nouso K, Miyahara K, Uchida D et al (2013) Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 109:1904-1907","journal-title":"Br J Cancer"},{"key":"1003_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1159\/000508724","volume":"9","author":"K Ueshima","year":"2020","unstructured":"Ueshima K, Ogasawara S, Ikeda M et al (2020) Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 9:583-595","journal-title":"Liver Cancer"},{"key":"1003_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K et al (2021) Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 10:181-223","journal-title":"Liver Cancer"},{"key":"1003_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL et al (2020) Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol 31:334-351","journal-title":"Ann Oncol"},{"key":"1003_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"Lyu N, Kong Y, Mu L et al (2018) Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol 69:60-69","journal-title":"J Hepatol"},{"key":"1003_CR19","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"He M, Li Q, Zou R et al (2019) Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol 5:953-960","journal-title":"JAMA Oncol"},{"key":"1003_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li QJ, He MK, Chen HW et al (2022) Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 40:150-160","journal-title":"J Clin Oncol"},{"key":"1003_CR21","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zhu X, Fu S et al (2022) Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology 303:455-464","journal-title":"Radiology"},{"issue":"Suppl 1","key":"1003_CR22","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.acra.2021.01.024","volume":"28","author":"SJ Hsu","year":"2021","unstructured":"Hsu SJ, Xu X, Chen MP et al (2021) Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. Acad Radiol 28 Suppl 1:S157-s166","journal-title":"Acad Radiol"},{"key":"1003_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00270-019-02406-3","volume":"43","author":"J Hu","year":"2020","unstructured":"Hu J, Bao Q, Cao G et al (2020) Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization\/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis. Cardiovasc Intervent Radiol 43:996-1005","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1003_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032390","volume":"101","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang J, Wang Y, Shu G, Lou C, Du Z (2022) HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 101:e32390","journal-title":"Medicine (Baltimore)"},{"key":"1003_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-023-01719-1","author":"X He","year":"2023","unstructured":"He X, Li K, Wei R et al (2023) A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Radiol Med. https:\/\/doi.org\/10.1007\/s11547-023-01719-1","journal-title":"Radiol Med"},{"key":"1003_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09953-x","author":"Z Xu","year":"2023","unstructured":"Xu Z, An C, Shi F et al (2023) Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-023-09953-x","journal-title":"Eur Radiol"},{"key":"1003_CR27","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1007\/s00432-022-04467-3","volume":"149","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Huang F, Liu S et al (2023) Prediction of therapeutic response of unresectable hepatocellular carcinoma to hepatic arterial infusion chemotherapy based on pretherapeutic MRI radiomics and Albumin-Bilirubin score. J Cancer Res Clin Oncol 149:5181-5192","journal-title":"J Cancer Res Clin Oncol"},{"key":"1003_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41568-018-0016-5","volume":"18","author":"A Hosny","year":"2018","unstructured":"Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts H (2018) Artificial intelligence in radiology. Nat Rev Cancer 18:500-510","journal-title":"Nat Rev Cancer"},{"key":"1003_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature14539","volume":"521","author":"Y LeCun","year":"2015","unstructured":"LeCun Y, Bengio Y, Hinton G (2015) Deep learning. Nature 521:436-444","journal-title":"Nature"},{"key":"1003_CR30","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1109\/TMI.2017.2715285","volume":"37","author":"H Huang","year":"2018","unstructured":"Huang H, Hu X, Zhao Y et al (2018) Modeling Task fMRI Data Via Deep Convolutional Autoencoder. IEEE Trans Med Imaging 37:1551-1561","journal-title":"IEEE Trans Med Imaging"},{"key":"1003_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247","journal-title":"Eur J Cancer"},{"key":"1003_CR32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/BF00402774","volume":"111","author":"R Bartkowski","year":"1986","unstructured":"Bartkowski R, Berger MR, Aguiar JL et al (1986) Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2\u2019-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model. J Cancer Res Clin Oncol 111:42-46","journal-title":"J Cancer Res Clin Oncol"},{"key":"1003_CR33","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000367746","volume":"4","author":"S Obi","year":"2015","unstructured":"Obi S, Sato S, Kawai T (2015) Current Status of Hepatic Arterial Infusion Chemotherapy. Liver Cancer 4:188-199","journal-title":"Liver Cancer"},{"key":"1003_CR34","doi-asserted-by":"publisher","first-page":"W211","DOI":"10.2214\/AJR.16.17398","volume":"209","author":"HJ Park","year":"2017","unstructured":"Park HJ, Kim JH, Choi SY et al (2017) Prediction of Therapeutic Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Based on Pretherapeutic Dynamic CT and Textural Findings. AJR Am J Roentgenol 209:W211-w220","journal-title":"AJR Am J Roentgenol"},{"key":"1003_CR35","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1007\/s00261-020-02891-y","volume":"46","author":"J Liu","year":"2021","unstructured":"Liu J, Pei Y, Zhang Y, Wu Y, Liu F, Gu S (2021) Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features. Abdom Radiol (NY) 46:3748-3757","journal-title":"Abdom Radiol (NY)"},{"key":"1003_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/jgh.12821","volume":"30","author":"D Miyaki","year":"2015","unstructured":"Miyaki D, Kawaoka T, Aikata H et al (2015) Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. J Gastroenterol Hepatol 30:726-732","journal-title":"J Gastroenterol Hepatol"},{"key":"1003_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jvir.2018.09.004","volume":"30","author":"N Lyu","year":"2019","unstructured":"Lyu N, Kong Y, Pan T et al (2019) Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread. J Vasc Interv Radiol 30:349-357.e342","journal-title":"J Vasc Interv Radiol"},{"key":"1003_CR38","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1126\/science.286.5439.531","volume":"286","author":"TR Golub","year":"1999","unstructured":"Golub TR, Slonim DK, Tamayo P et al (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286:531-537","journal-title":"Science"},{"key":"1003_CR39","doi-asserted-by":"publisher","first-page":"7185","DOI":"10.1007\/s00330-022-08927-9","volume":"32","author":"B Liu","year":"2022","unstructured":"Liu B, Zeng Q, Huang J et al (2022) IVIM using convolutional neural networks predicts microvascular invasion in HCC. Eur Radiol 32:7185-7195","journal-title":"Eur Radiol"},{"key":"1003_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S2468-1253(18)30078-5","volume":"3","author":"M Kudo","year":"2018","unstructured":"Kudo M, Ueshima K, Yokosuka O et al (2018) Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 3:424-432","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Imaging Informatics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10278-024-01003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10278-024-01003-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10278-024-01003-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T17:10:26Z","timestamp":1722877826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10278-024-01003-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1007\/s10278-024-01003-2","relation":{},"ISSN":["2948-2933"],"issn-type":[{"value":"2948-2933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board approval was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the information in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}